Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0FT0J
|
||||
| Former ID |
DIB019695
|
||||
| Drug Name |
d-AP5
|
||||
| Synonyms |
D-AP-5; D-aminophosphonovaleric acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [467507] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C5H11NO5P-
|
||||
| InChI |
InChI=1S/C5H12NO5P/c6-4(5(7)8)2-1-3-12(9,10)11/h4H,1-3,6H2,(H,7,8)(H2,9,10,11)/p-1/t4-/m1/s1
|
||||
| InChIKey |
VOROEQBFPPIACJ-SCSAIBSYSA-M
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | GluN2C | Target Info | Antagonist | [543839] | |
| GluN2D | Target Info | Antagonist | [543840] | ||
| Glutamate [NMDA] receptor subunit epsilon 2 | Target Info | Antagonist | [543838] | ||
| Glutamate [NMDA] receptor subunit epsilon 1 | Target Info | Antagonist | [543837] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Huntington's disease | |||||
| Cocaine addiction | |||||
| Amphetamine addiction | |||||
| Nicotine addiction | |||||
| Alcoholism | |||||
| Systemic lupus erythematosushsa04014:Ras signaling pathway | |||||
| Calcium signaling pathway | |||||
| Systemic lupus erythematosus | |||||
| PANTHER Pathway | Huntington disease | ||||
| Ionotropic glutamate receptor pathway | |||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| Pathway Interaction Database | ErbB4 signaling events | ||||
| Reelin signaling pathwayreelinpathway:Reelin signaling pathway | |||||
| Reactome | EPHB-mediated forward signaling | ||||
| Unblocking of NMDA receptor, glutamate binding and activation | |||||
| CREB phosphorylation through the activation of CaMKII | |||||
| Ras activation uopn Ca2+ infux through NMDA receptor | |||||
| RAF/MAP kinase cascadeR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation | |||||
| RAF/MAP kinase cascade | |||||
| References | |||||
| Ref 543837 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). | ||||
| Ref 543838 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). | ||||
| Ref 543839 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). | ||||
| Ref 543840 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.